Wheezo by the numbers, page-4

great summary Mondy.

the company disclosed in the recent half year report, that supply for Q1 has been delayed due to a Covid related supply chain interruption. Marjan then explained in a recent presentation, that this was a one-off factor, that has now been addressed.

However, the company is expecting this supply to land in April, and we already know that Cipla (the customer) has made an initial commitment of 7k units. So Cipla will likely make a 4K purchase (3k previously bought) shortly after the stock is available.

so from April onwards, we can then look forward to

- consistent monthly supply that is ramping up (& preparing for UK launch in Q4)
- Wheezo in an increasing amount of pharmacy stores
- effective, low cost marketing + in-store customer engagement activities ramping up

As yenom has previously stated, there is no point assessing Aus based customer demand until the infrastructure (supply, pharmacy agreements etc) is in place. In my mind it will be Q3 and Q4 CY2021, that will provide an accurate representation of Australian based customer demand.

Reading recent announcements provides evidence that there is also no shortage of background de-risking & growth related activities such as physician/KOL engagement, overseas launch preparation, studies etc that will add significant value to the company in 6/12/18 months.